Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Core Insights - Nkarta, Inc. is focused on developing engineered natural killer (NK) cell therapies for autoimmune diseases, with a strong emphasis on clinical trial execution and the potential of NK cell therapy to meet unmet medical needs [2][3]. Financial Highlights - For the second quarter of 2025, Nkarta reported a net loss of $23.0 million, or $0.31 per share, with research and development expenses amounting to $20.8 million and general and administrative expenses of $6.4 million [10][20]. - The company had a cash balance of $334.0 million as of June 30, 2025, which is expected to fund operations into 2029 [5][8]. Clinical Program Updates - The NKX019 clinical program is progressing with ongoing patient enrollment in the Ntrust-1 and Ntrust-2 trials, which focus on safety and long-term remission in autoimmune diseases [6][9]. - Initial updates for NKX019 in multiple autoimmune indications are anticipated in the second half of 2025 [8][9]. Leadership and Expertise - Dr. Shawn Rose was appointed as Chief Medical Officer and Head of Research and Development in June 2025, bringing extensive experience in rheumatology and drug development for autoimmune conditions [3][4]. Clinical Trials Overview - Ntrust-1 and Ntrust-2 are multi-center, open-label, dose escalation trials assessing NKX019's safety and efficacy in patients with various autoimmune diseases, including lupus nephritis and systemic sclerosis [6][7][11]. - The trials involve a three-dose cycle of NKX019, designed to evaluate its single-agent activity without supplemental cytokines or antibody-based therapeutics [11][12].